Overview

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Status:
Active, not recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to assess the efficacy and safety of single-agent olaparib as a maintenance treatment in patients with relapsed High Grade Serous Ovarian Cancer (including patients with primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer who do not have known deleterious or suspected deleterious germline BRCA mutations (non-gBRCAm) and who had responded following platinum based chemotherapy

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

Covance
Iqvia Pty Ltd
Myriad Genetics, Inc.
Parexel
Quintiles, Inc.
Theradex

Treatments:

Olaparib